Literature DB >> 7945733

MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac).

E T Leonardi1, E C Azmitia.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA), a serotonin (5-HT) neurotoxin, has been shown to promote the release of serotonin (5-HT) and block its reuptake. The increased buildup of extracellular 5-HT should normally be degraded by monoamine oxidase (MAO). The effects of both enantiomers of MDMA were examined on MAO-A and monoamine oxidase-B (MAO-B) activity in rat brain homogenates. Both enantiomers competitively inhibited 5-HT catabolism by rat brain MAO-A. The Ki of MDMA for MAO-A was 22 mumol/L. A mixed type of inhibition by MDMA was observed for phenethylamine catabolism by MAO-B for both optical antipodes. Logistical analysis of concentration response curves for MDMA inhibition of MAO-A and MAO-B show an IC50 of 44 mumol/L for inhibition of MAO-A by MDMA. The IC50 value of MDMA inhibition of MAO-B was 370 mumol/L, showing a selective potency for MAO-A inhibition. The MAO inhibitory properties of fenfluramine (FEN) and fluoxetine (FLUOX) were compared to those of MDMA. The rank order potency of these drugs for MAO-A inhibition was MDMA > FLUOX > FEN, whereas for MAO-B inhibition, FLUOX > MDMA > FEN. A combination of FLUOX and MDMA at their respective IC50 did not inhibit MAO activity more than either drug alone at equivalent concentrations. These results indicate that the actions of FEN do not appear to involve MAO inhibition. MDMA (ecstasy) produced a preferential inhibition of MAO-A (IC50 = 44 mumol/L), which should increase extracellular 5-HT.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945733     DOI: 10.1038/npp.1994.26

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  28 in total

Review 1.  The preclinical pharmacology of mephedrone; not just MDMA by another name.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 2.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

Review 3.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

4.  Concurrent Inhibition of Vesicular Monoamine Transporter 2 Does Not Protect Against 3,4-Methylenedioxymethamphetamine (Ecstasy) Induced Neurotoxicity.

Authors:  Aram B Cholanians; Andy V Phan; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2019-07-01       Impact factor: 4.849

Review 5.  The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Authors:  J R Docherty; A R Green
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 6.  Kinetics, mechanism, and inhibition of monoamine oxidase.

Authors:  Rona R Ramsay; Alen Albreht
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

7.  Cardiac effects of MDMA on the metabolic profile determined with 1H-magnetic resonance spectroscopy in the rat.

Authors:  Shane A Perrine; Mark S Michaels; Farhad Ghoddoussi; Elisabeth M Hyde; Manuel E Tancer; Matthew P Galloway
Journal:  NMR Biomed       Date:  2009-05       Impact factor: 4.044

8.  Further Electrochemical and Behavioural Evidence of a Direct Relationship Between Central 5-HT and Cytoskeleton in the Control of Mood.

Authors:  Francesco Crespi
Journal:  Open Neurol J       Date:  2010-05-21

9.  Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women.

Authors:  Marta Concheiro; Hendreé Jones; Rolley E Johnson; Diaa M Shakleya; Marilyn A Huestis
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-01-01       Impact factor: 3.205

10.  Inhibition of rat brain monoamine oxidase enzymes by fluoxetine and norfluoxetine.

Authors:  A Holt; G B Baker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.